Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Avesani, Barbara
Giontella, Elena
Caldart, Alberto
De Noni, Alessandro
Muzzarelli, Alice
Borghesani, Giulia
Insolda, Jessica
Biondani, Pamela
Parolin, Veronica
Pellini, Francesca
Scarpa, Aldo
Nottegar, Alessia
Lawlor, Rita T.
Mafficini, Andrea
Paris, Ida
Minucci, Angelo
Pasciuto, Tina
Fabi, Alessandra
Fiorio, Elena
Milella, Michele
机构：
[1] Azienda Osped Univ Integrata Verona, Med Oncol, Verona, Italy
[2] Azienda Osped Univ Integrata Verona, Verona, Italy
[3] Azienda Osped Univ Integrata Verona, Sect Breast Surg, Verona, Italy
[4] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Hosp Trust Verona, Verona, Italy
[6] Univ Verona, Sect Pathol, Verona, Italy
[7] ARC NET, Verona, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[9] Univ Cattolica Sacro Cuore, Dept Unit Mol & Genom Diagnost, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy
[11] IRCCS, Precis Med Senol, Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[12] Univ Verona Hosp Trust, Dept Oncol, Verona, Italy
[13] Univ Verona, Sch Med, Sect Oncol, Verona, Italy
[14] Verona Univ Hosp Trust, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13079
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
    Martinez-Janez, Noelia
    Ezquerra, Meritxell Bellet
    Henao, Fernando
    Manso, Luis
    Anton, Antonio
    Zamora, Pilar
    Murillo, Serafin Morales
    Tolosa, Pablo
    Andres, Raquel
    Calvo, Lourdes
    Galve, Elena
    Lopez, Rafael
    de la Pena, Francisco Ayala
    Lopez-Tarruella, Sara
    Boronat, Laia
    Martos, Tamara
    Chacon, J. Ignacio
    Alvarez, Isabel
    de la Haba-Rodriguez, Juan
    Anton, Fernando Moreno
    CANCER RESEARCH, 2023, 83 (05)
  • [42] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Tolaney, Sara M.
    Punie, Kevin
    Kurian, Allison W.
    Ntalla, Ioanna
    Verret, Wendy
    Sadetsky, Natalia
    Sjekloca, Nikoleta
    Stokes, Michael
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [44] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [45] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S11 - S12
  • [46] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S11 - S12
  • [47] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [48] Impact of hormone receptor expression level in HR+/HER2-metastatic breast cancer in the large French ESME cohort
    Alexandre, Marie
    Castan, Florence
    Rouge, Thibault De La Motte
    Mailliez, Audrey
    Brain, Etienne
    Bachelot, Thomas
    Arnedos, Monica
    Dalenc, Florence
    Ferrero, Jean-Marc
    Massard, Vincent
    Desmoulins, Isabelle
    Mouret-Reynier, Marie-Ange
    Levy, Christelle
    Goncalves, Anthony
    Berghian, Anca
    Savoye, Aude-Marie
    Frenel, Jean-Sebastien
    Bosquet, Lise
    Delaloge, Suzette
    Jacot, William
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer
    Guerin, Annie
    Goldschmidt, Debbie
    Small, Tania
    Gagnon-Sanschagrin, Patrick
    Romdhani, Hela
    Gauthier, Genevieve
    Kelkar, Sneha
    Wu, Eric Q.
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (08) : 1251 - 1264
  • [50] Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
    Song, Yan
    Hao, Yanni
    Macalalad, Alexander R.
    Lin, Peggy L.
    Signorovitch, James E.
    Wu, Eric Q.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 67 - 72
12345